16/05/24 | 5:52 pm

Print

Researchers discover new biomarker to diagnose Alzheimer’s in asymptomatic stages

A novel biomarker for Alzheimer’s disease in its asymptomatic phases has been discovered by a recent study headed by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona.

The molecule is called miR-519a-3p, and it is a microRNA that has been directly connected to the expression of the cellular prion protein (PrPC), which is dysregulated in patients with Alzheimer’s disease and other neurodegenerative illnesses.

The hunt for stable, readily observable biomarkers in biofluids, such as microRNAs, presents a chance to identify Alzheimer’s early on when the disease is asymptomatic. This condition, which affects over 35 million people globally, might be diagnosed and treated far more effectively with early detection.

The expression of some microRNAs is known to be deregulated in Alzheimer’s patients. However, this is the first time that this microRNA has been specifically linked to the decrease in cellular prion protein production during disease progression.

“Currently, tests to diagnose Alzheimer’s disease are usually carried out after the onset of symptoms, when there is already underlying cognitive impairment. We believe that the detection of this microRNA may help to establish additional criteria for a more accurate diagnosis in the early stages of the disease,” explains IBEC principal investigator Jose Antonio del Rio, full professor at the Faculty of Biology and the Institute of Neurosciences of the University of Barcelona (UB) and co-leader of the study.

The study also comparatively analyzes the presence of the biomarker in samples from other neurodegenerative diseases.

“If our goal is to use miR-519a-3p as a biomarker to detect Alzheimer’s dementia in hypothetically healthy people, it is essential to ensure that its levels are not altered in other neurodegenerative diseases.”

“In our study, we compared the levels of this biomarker in samples from other tauopathies and Parkinson’s disease, confirming that the changes in miR-519a-3p are specific to Alzheimer’s disease,” said IBEC senior researcher Rosalina Gavin, UB associate professor, and co-leader of the study.”

(ANI)

RELATED ARTICLES

40 mins ago | ind vs nz

NZ skipper Latham highlights Bumrah challenge; hails Kiwis pace “leader” Matt Henry ahead of 1st Test against India

New Zealand skipper Tom Latham spoke on Kiwis facing Indian pace superstar Jasprit Bumrah, saying that his unique action is going to make facing him a huge challenge. Following India's series wins in the T20I and ODI legs of the series, the inaugu...

41 mins ago | Finance and Contract Committee

Municipal Corporation of Gurugram approves development projects worth Rs 61 crore

The Municipal Corporation of Gurugram (MCG) has approved development projects and civic amenities worth over Rs 61.10 crore at the 11th meeting of its Finance and Contract Committee (F&CC), an official said. The meeting was held on Tuesday under...

46 mins ago | US and Iran

US, Iran exchange fire despite talks with mediators

The US and Iran exchanged fire on Tuesday, with the US striking an Iranian missile launch site after Iran said it targeted a US military radar system in Bahrain, despite talks between Iran and mediators Oman and Qatar. The latest back-and-forth betw...